Avoro Capital Advisors LLC Biomarin Pharmaceutical Inc Transaction History

Avoro Capital Advisors LLC

$6.65 Billion
Q3 2024

A detailed history of Avoro Capital Advisors LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Avoro Capital Advisors LLC holds 2,038,015 shares of BMRN stock, worth $134 Million. This represents 2.16% of its overall portfolio holdings.

Number of Shares

2,038,015

Previous 4,557,416 55.28%

Holding current value

$134 Million

Previous $375 Million 61.82%

% of portfolio

2.16%

Previous 5.12%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$69.02 - $93.84 $174 Million - $236 Million	-2,519,401 Reduced 55.28%	2,038,015 $143 Million
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $14.3 Million - $17.7 Million	192,416 Added 4.41%	4,557,416 $375 Million
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $5.45 Million - $6.44 Million	65,000 Added 1.51%	4,365,000 $381 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $34.3 Million - $44.3 Million	450,000 Added 11.69%	4,300,000 $415 Million
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $12.8 Million - $14.2 Million	-150,000 Reduced 3.75%	3,850,000 $341 Million
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $4.77 Million - $5.52 Million	55,000 Added 1.39%	4,000,000 $347 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $34.2 Million - $45.7 Million	389,445 Added 10.95%	3,945,000 $384 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $22.3 Million - $26.3 Million	271,555 Added 8.27%	3,555,555 $301 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $17.8 Million - $21.6 Million	249,000 Added 8.2%	3,284,000 $272 Million
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $17.5 Million - $21.8 Million	235,000 Added 8.39%	3,035,000 $234 Million
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $66.3 Million - $84.6 Million	925,000 Added 49.33%	2,800,000 $247 Million
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $16.8 Million - $19.2 Million	225,000 Added 13.64%	1,875,000 $145 Million
Q4 2020 Feb 16, 2021	SELL	$72.61 - $90.2 $7.26 Million - $9.02 Million	-100,000 Reduced 5.71%	1,650,000 $145 Million
Q3 2020 Nov 16, 2020	SELL	$71.87 - $131.03 $7.19 Million - $13.1 Million	-100,000 Reduced 5.41%	1,750,000 $133 Million
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $6.36 Million - $9.94 Million	-80,000 Reduced 4.15%	1,850,000 $228 Million
Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $5 Million - $6.78 Million	-70,000 Reduced 3.5%	1,930,000 $163 Million
Q4 2019 Feb 14, 2020	SELL	$64.27 - $86.37 $28.1 Million - $37.8 Million	-437,100 Reduced 17.94%	2,000,000 $169 Million
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $21.7 Million - $27.4 Million	322,100 Added 15.23%	2,437,100 $164 Million
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $79.9 Million - $93.4 Million	995,000 Added 88.84%	2,115,000 $181 Million
Q1 2019 May 15, 2019	SELL	$84.2 - $98.62 $20.2 Million - $23.7 Million	-240,000 Reduced 17.65%	1,120,000 $99.5 Million
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $649,374 - $859,485	-8,103 Reduced 0.59%	1,360,000 $116 Million
Q3 2018 Nov 14, 2018	SELL	$93.92 - $105.72 $23.9 Million - $26.9 Million	-254,667 Reduced 15.69%	1,368,103 $133 Million
Q2 2018 Aug 14, 2018	SELL	$76.01 - $99.03 $6.71 Million - $8.74 Million	-88,225 Reduced 5.16%	1,622,770 $153 Million
Q1 2018 May 15, 2018	BUY	$77.67 - $92.63 $40.5 Million - $48.3 Million	521,471 Added 43.84%	1,710,995 $139 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $47.8 Million - $56.3 Million	591,552 Added 98.93%	1,189,524 $106 Million
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $48.2 Million - $56.8 Million	597,972	597,972 $55.7 Million

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.2B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Avoro Capital Advisors LLC with notifications on news.

Account

Avoro Capital Advisors LLC Biomarin Pharmaceutical Inc Transaction History